journal
MENU ▼
Read by QxMD icon Read
search

Hepatology Research: the Official Journal of the Japan Society of Hepatology

journal
https://www.readbyqxmd.com/read/30198141/proton-pump-inhibitor-therapy-does-not-increase-serum-endotoxin-activity-in-patients-with-cirrhosis
#1
Yasushi Okura, Tadashi Namisaki, Shinya Sato, Kei Moriya, Takemi Akahane, Mitsuteru Kitade, Hideto Kawaratani, Kosuke Kaji, Hiroaki Takaya, Yasuhiko Sawada, Naotaka Shimozato, Kenichiro Seki, Soichiro Saikawa, Keisuke Nakanishi, Masanori Furukawa, Yukihisa Fujinaga, Takuya Kubo, Daisuke Kaya, Yuki Tsuji, Takahiro Ozutsumi, Koh Kitagawa, Tsuyoshi Mashitani, Hiroyuki Ogawa, Koji Ishida, Akira Mitoro, Junichi Yamao, Hitoshi Yoshiji
AIM: Proton pump inhibitors (PPIs) are frequently prescribed in patients with cirrhosis, but this therapy entails potential complications. We aimed to investigate the influence of PPI use on intestinal permeability in patients with cirrhosis. METHODS: We recruited 228 patients with cirrhosis and divided them into four groups. Group (Gp)1 comprised patients receiving a PPI with concurrent neomycin (NEO) [PPI-NEO group; n = 14 (6.1%)], Gp2 and Gp3 comprised those receiving either PPI or NEO [PPI group; n = 91 (39...
September 9, 2018: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/30182424/identification-of-liver-fibrosis-using-the-hepatic-vein-waveform-in-patients-with-fontan-circulation
#2
Takuma Nakatsuka, Yoko Soroida, Hayato Nakagawa, Takahiro Shindo, Masaya Sato, Katsura Soma, Ryo Nakagomi, Tamaki Kobayashi, Momoe Endo, Hiromi Hikita, Mamiko Sato, Hiroaki Gotoh, Tomomi Iwai, Mariko Yasui, Aya Shinozaki-Ushiku, Kazuhiro Shiraga, Hiroko Asakai, Yoichiro Hirata, Masashi Fukayama, Hitoshi Ikeda, Yutaka Yatomi, Ryosuke Tateishi, Ryo Inuzuka, Kazuhiko Koike
AIM: Liver fibrosis caused by congestive hepatopathy has emerged as an important complication after Fontan procedure. We evaluated the utility of the hepatic vein (HV) waveform using Doppler ultrasound for identification of liver fibrosis in Fontan patients. METHODS: We investigated the HV waveforms in 41 Fontan patients and assessed correlations with clinical parameters, liver fibrosis markers, and hemodynamic data. RESULTS: Based on our preliminary analysis of 64 adult patients with chronic liver disease who underwent liver biopsy, we classified HV waveforms into five types with reference to the degree of flattening (from type 1, normal triphasic waveform; to type 5, a monophasic waveform indicating cirrhosis), and confirmed a significant correlation between waveform pattern and fibrosis stage...
September 4, 2018: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/30180287/spontaneous-regression-of-hepatocellular-carcinoma-with-reduction-in-angiogenesis-related-cytokines-after-treatment-with-sodium-glucose-cotransporter-2-inhibitor-in-a-cirrhotic-patient-with-diabetes-mellitus-a-case-report
#3
Takumi Kawaguchi, Dan Nakano, Shusuke Okamura, Shigeo Shimose, Masako Hayakawa, Takashi Niizeki, Hironori Koga, Takuji Torimura
Spontaneous regression of hepatocellular carcinoma (HCC) is a rare event, and the pathogenesis remains unclear. Here, we present a case of spontaneous regression of HCC after treatment with sodium-glucose cotransporter 2 inhibitor (SGLT2i) in a cirrhotic patient with diabetes mellitus (DM). A 68-year-old man regularly visited our hospital for follow-up of HCC post treatment of transcatheter arterial chemoembolization, and management of liver cirrhosis and type 2 DM. Contrast-enhanced computed tomography scan showed a hypervascular tumor in the liver and elevated serum alpha-fetoprotein levels, indicating the recurrence of HCC...
September 4, 2018: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/30171740/real-world-efficacy-and-safety-of-sofosbuvir-ribavirin-for-hepatitis-c-genotype-2-a-nationwide-multicenter-study-by-the-japanese-red-cross-liver-study-group
#4
Takehiro Akahane, Masayuki Kurosaki, Jun Itakura, Keiji Tsuji, Kouji Joko, Hiroyuki Kimura, Akihiro Nasu, Chikara Ogawa, Yuji Kojima, Chitomi Hasebe, Shuichi Wada, Yasushi Uchida, Tetsuro Sohda, Hideyuki Suzuki, Hideo Yoshida, Atsunori Kusakabe, Takashi Tamada, Haruhiko Kobashi, Akeri Mitsuda, Masahiko Kondo, Masaya Shigeno, Yasushi Ide, Atsuhiro Morita, Tadashi Kitamura, Takehiko Abe, Namiki Izumi
AIM: This study aimed to describe the real-world efficacy and safety of sofosbuvir (SOF) + ribavirin (RBV) for chronic hepatitis C, genotype 2. METHODS: This was a retrospective analysis of a nationwide, multicenter registry including 914 hepatitis C genotype 2 Japanese patients treated with SOF + RBV for 12 weeks. The rate of sustained virological response at 12 weeks after treatment (SVR12), incidence of adverse events, and changes in serological parameters was analyzed...
September 1, 2018: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/30156741/effect-of-loop-diuretics-on-skeletal-muscle-depletion-in-patients-with-liver-cirrhosis
#5
Tatsunori Hanai, Makoto Shiraki, Takao Miwa, Satoshi Watanabe, Kenji Imai, Atsushi Suetsugu, Koji Takai, Hisataka Moriwaki, Masahito Shimizu
AIM: Sarcopenia, the loss of skeletal muscle mass, impairs prognosis of patients with liver cirrhosis. The aim of this study was to investigate the effect of loop diuretics, which are frequently used to treat hepatic edema/ascites, on skeletal muscle depletion and the prognosis in patients with liver cirrhosis. METHODS: This retrospective study evaluated 226 patients with liver cirrhosis. The skeletal muscle cross-sectional area at the level of the third lumbar vertebra was measured using computed tomography...
August 29, 2018: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/30156739/cyp7a1-expression-in-hepatocytes-is-retained-with-upregulated-fibroblast-growth-factor-19-in-pediatric-biliary-atresia
#6
Yasuhiro Hasegawa, Masanobu Kawai, Kazuhiko Bessho, Kie Yasuda, Takehisa Ueno, Yoshinori Satomura, Akiko Konishi, Takeshi Kimura, Kayo Ikeda, Makiko Tachibana, Yoko Miyoshi, Toshimi Michigami, Hiroki Kondou, Keiichi Ozono
AIM: Bile acid biosynthesis is strictly regulated under physiological conditions. The expression of fibroblast growth factor (FGF) 19 is induced when bile acids bind to the farnesoid X receptor in the intestinal epithelium. FGF19 is then transported via the portal flow, causing transcriptional inhibition of cytochrome P450, family 7, subfamily A, polypeptide 1 (CYP7A1)-a key enzyme in bile acid biosynthesis-via the extracellular signal-regulated kinase (ERK) pathway. However, the regulatory mechanisms of these signaling pathways in hepatocytes under chronic cholestasis remain unclear...
August 29, 2018: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/30144256/therapeutic-potential-of-lenvatinib-for-unresectable-hepatocellular-carcinoma-in-clinical-practice-multicenter-analysis
#7
Atsushi Hiraoka, Takashi Kumada, Kazuya Kariyama, Koichi Takaguchi, Ei Itobayashi, Noritomo Shimada, Kazuto Tajiri, Kunihiko Tsuji, Toru Ishikawa, Hironori Ochi, Masashi Hirooka, Akemi Tsutsui, Hiroshi Shibata, Toshifumi Tada, Hidenori Toyoda, Kazuhiro Nouso, Kouji Joko, Yoichi Hiasa, Kojiro Michitaka
BACKGROUND/AIM: Lenvatinib (LEN) has recently become available as a first-line tyrosine-kinase inhibitor (TKI) for unresectable hepatocellular carcinoma (u-HCC). In patients who showed intolerability or failure in other TKI treatments, alternative treatment option has been needed. This retrospective study evaluated the therapeutic potential of LEN in clinical practice. MATERIALS/METHODS: We enrolled 57 u-HCC patients treated with LEN from March to June 2018. LEN was administered orally to patients weighing <60kg at 8 mg/day and at 12 mg/day to those ≥60kg...
August 24, 2018: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/30125438/efficacy-and-safety-of-elbasvir-plus-grazoprevir-combination-therapy-in-japanese-patients-infected-with-hcv-genotype-1b
#8
Yasue Takeuchi, Norio Akuta, Hitomi Sezaki, Fumitaka Suzuki, Shunichiro Fujiyama, Yusuke Kawamura, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Satoshi Saitoh, Yoshiyuki Suzuki, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada
AIM: Treatment with all-oral direct-acting antiviral agents (DAA) elbasvir/grazoprevir (EBR/GZR) is associated with high sustained virologic response (SVR). The aim of this study was to evaluate the safety and treatment efficacy of EBR/GZR in HCV-infected patients. METHODS: This retrospective cohort study included 147 consecutive patients with chronic HCV genotype 1b infection were treated with EBR (50 mg) plus GZR (100 mg) once-daily for 12 weeks. SVR12 rates were evaluated based on patient baseline characteristics...
August 19, 2018: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/30117236/microvascular-invasion-predicts-a-poor-prognosis-of-solitary-hepatocellular-carcinoma-up-to-2-cm-based-on-propensity-score-matching-analysis
#9
Han Wang, Meng-Chao Wu, Wen-Ming Cong
AIM: Microvascular invasion (MVI) is not discussed for solitary hepatocellular carcinoma (HCC) up to 2 cm in the 8th Edition of the American Joint Committee on Cancer Staging Manual. The present study aimed to reappraise the influence of MVI on solitary HCC up to 2 cm in diameter. METHODS: Between January 2010 and December 2012, a retrospective cohort of 496 HCC patients from the Eastern Hepatobiliary Surgery Hospital was analyzed. Propensity score matching was carried out to balance the baseline characteristics...
August 16, 2018: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/30084205/risk-factors-and-outcomes-of-acute-respiratory-distress-syndrome-in-critically-ill-patients-with-cirrhosis
#10
Philip Yang, Perry Formanek, Steven Scaglione, Majid Afshar
AIM: Prior randomized controlled trials of acute respiratory distress syndrome (ARDS) excluded critically ill patients with cirrhosis. Data regarding risk factors for ARDS development and outcomes from ARDS in patients with cirrhosis are scarce. We sought to characterize outcomes from ARDS in patients with cirrhosis. METHODS: An observational cohort of patients with cirrhosis admitted to an intensive care unit at a high-volume liver transplant center between 1 January 2012 and 31 December 2014 were reviewed...
August 7, 2018: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/30084186/accuracy-of-calprotectin-using-the-quantum-blue-reader-for-the-diagnosis-of-spontaneous-bacterial-peritonitis-in-liver-cirrhosis
#11
Delphine Weil, Alexandra Heurgue-Berlot, Elisabeth Monnet, Sophie Chassagne, Jean-Paul Cervoni, Thomas Feron, Céline Grandvallet, Emilie Muel, Jean-Pierre Bronowicki, Gérard Thiefin, Vincent Di Martino, Karine Bardonnet, Thierry Thévenot
AIM: We aimed to evaluate the accuracy of the dosage of calprotectin in ascitic fluid (AF) using the Quantum Blue assay, for the prompt diagnosis of spontaneous bacterial peritonitis (SBP). METHODS: We prospectively collected 236 AF samples from 119 cirrhotic patients hospitalized in two French centers between May 2016 and May 2017. Bloody and chylous/cloudy AF, and secondary peritonitis were excluded. SBP was diagnosed if neutrophils in AF were >250/mm3 using standard cytology...
August 7, 2018: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/30084146/re-examination-using-newly-proposed-diagnostic-criteria-of-acute-on-chronic-liver-failure-in-japan
#12
LETTER
Shunsuke Nojiri, Atsunori Tsuchiya, Shuji Terai
No abstract text is available yet for this article.
August 7, 2018: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/30058778/-the-clinicopathological-investigation-about-steatohepatitic-hepatocellular-carcinoma-a-multicenter-study-using-immunohistochemical-analysis-of-adenoma-related-markers
#13
Makiko Taniai, Etsuko Hashimoto, Maki Tobari, Kazuhisa Kodama, Katsutoshi Tokushige, Masakazu Yamamoto, Tadatoshi Takayama, Masahiko Sugitani, Keiji Sano, Fukuo Kondo, Toshio Fukusato
AIMS: Steatohepatitic hepatocellular carcinoma (SH-HCC) is a newly proposed concept, which shows histological features of steatohepatitis in HCC lesion, and it is strongly associated with metabolic syndrome (MS) and steatosis/steatohepatitis in non-cancerous lesion. Recently, a substantial number of HCC associated with MS was reported to have developed from preexisting inflammatory hepatocellular adenoma (HCA). To elucidate characteristic features of SH-HCC, we made clinicopathological investigations on strictly diagnosed SH-HCC and non-SH-HCC (standard HCC)...
July 30, 2018: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/30051950/complete-response-by-vitamin-k2-analog-monotherapy-in-sorafenib-failure-advanced-hepatocellular-carcinoma-a-case-report
#14
Teiji Kuzuya, Masatoshi Ishigami, Yoji Ishizu, Takashi Honda, Kazuhiko Hayashi, Tetsuya Ishikawa, Yoshiki Hirooka, Hidemi Goto
There have been reports that a vitamin K2 (VK2) analog is beneficial for the prevention of recurrence in hepatocellular carcinoma (HCC) patients after curative therapy. However, the VK2 analogs in current use do not appear to show dramatic antitumor effects when given alone. Here, we report the case of a 67-year-old male patient with sorafenib-failure advanced HCC who achieved complete response (CR) after VK2 analog monotherapy. At the time of sorafenib failure confirmation, the patient had multiple intrahepatic tumors, multiple lung metastases, and Vp3 portal vein tumor thrombosis...
July 27, 2018: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/30051943/effect-of-luseogliflozin-on-hepatic-fat-content-in-type-2-diabetes-patients-with-non-alcoholic-fatty-liver-disease-a-prospective-single-arm-trial-lead-trial
#15
Yoshio Sumida, Kenta Murotani, Miyoko Saito, Atsuko Tamasawa, Yusuke Osonoi, Masashi Yoneda, Takeshi Osonoi
AIMS: No pharmacological therapies are approved for non-alcoholic fatty liver disease (NAFLD). Luseogliflozin, a sodium glucose cotransporter 2 inhibitor, has been developed for the treatment of adults with type 2 diabetes (T2DM). The aim of this prospective, single-arm study is to evaluate the efficacy of luseogliflozin on hepatic fat content and glycated hemoglobin (HbA1c) in T2DM patients with NAFLD. METHODS: Forty T2DM patients with NAFLD were treated with luseogliflozin 2...
July 27, 2018: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/30048035/sustained-virologic-response-after-eight-weeks-of-treatment-with-sofosbuvir-ledipasvir-and-ribavirin-in-a-decompensated-cirrhotic-patient-with-hepatitis-c-virus-genotype-1b
#16
Ohki Taniyama, Seiichi Mawatari, Kohei Oda, Kazuaki Tabu, Sho Ijuin, Kotaro Kumagai, Ai Kasai, Shuzo Tashima, Tsutomu Tamai, Akihiro Moriuchi, Akio Ido
A 68-year-old Japanese man with decompensated cirrhosis due to hepatitis C virus (HCV) genotype 1b infection was treated with sofosbuvir (SOF; 400 mg/day), ledipasvir (LDV; 90 mg/day), and ribavirin (RBV; 400 mg/day). Before treatment, his Child-Pugh and Model for End-Stage Liver Disease (MELD) scores were 10 (class C) and 13 points, respectively. Although RBV was initially given at two-thirds the normal dose due to anemia, his hemoglobin level gradually declined, and RBV was reduced to 200 mg daily on day 11, and 200 mg every other day on day 14...
July 26, 2018: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/30048033/homocysteine-supplementation-ameliorates-steatohepatitis-induced-by-a-choline-deficient-diet-in-mice
#17
Shinichiro Minami, Kouichi Miura, Mitsuaki Ishioka, Naoki Morimoto, Norio Isoda, Hironori Yamamoto, Katsunori Iijima
AIM: High concentrations of homocysteine are believed to induce lipid synthesis and cell injury through endoplasmic reticulum (ER) stress in metabolic syndrome. However, homocysteine could be used to improve steatohepatitis induced by choline deficiency, in which methyl donors are decreased. The aim of the present study was to clarify the role of the physiological concentration of homocysteine in the development of steatohepatitis induced by choline deficiency. METHODS: Wild-type mice were fed a choline-deficient amino acid-defined (CDAA) diet with or without homocysteine supplementation for 24 weeks...
July 26, 2018: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/30030881/comparison-of-hepatic-arterial-infusion-chemotherapy-between-5-fluorouracil-based-continuous-infusion-chemotherapy-and-low-dose-cisplatin-monotherapy-for-advanced-hepatocellular-carcinoma
#18
Tomokazu Kawaoka, Hiroshi Aikata, Tomoki Kobayashi, Shinsuke Uchikawa, Kazuki Ohya, Kenichiro Kodama, Yuno Nishida, Kana Daijo, Mitsutaka Osawa, Yuji Teraoka, Yuki Inagaki, Fumi Honda, Masahiro Hatooka, Kei Morio, Reona Morio, Hatsue Fujino, Takashi Nakahara, Eisuke Murakami, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Yoshiiku Kawakami, Yasutaka Baba, Kazuo Awai, Kazuaki Chayama
AIM: The aim of this study is to compare the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) between 5-fluorouracil (5-FU)-based continuous infusion chemotherapy and low-dose cisplatin (CDDP) monotherapy in patients with advanced hepatocellular carcinoma (HCC). METHODS: Patients were grouped according to HAIC regimen (5-FU group, n = 317/CDDP group, n = 66). A two-to-one match was created using propensity score analysis (5-FU group, n = 102/CDDP group, n = 51)...
July 20, 2018: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/30030872/wisteria-floribunda-agglutinin-positive-mac-2-binding-protein-predicts-early-occurrence-of-hepatocellular-carcinoma-after-sustained-virologic-response-by-direct-acting-antivirals-for-hepatitis-c-virus
#19
Yutaka Yasui, Masayuki Kurosaki, Yasuyuki Komiyama, Hitomi Takada, Nobuharu Tamaki, Keiya Watakabe, Mao Okada, Wan Wang, Takao Shimizu, Yohei Kubota, Mayu Higuchi, Kenta Takaura, Kaoru Tsuchiya, Hiroyuki Nakanishi, Yuka Takahashi, Jun Itakura, Nobuyuki Enomoto, Namiki Izumi
AIM: The aim of this study is to clarify the value of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA+ -M2BP) for predicting hepatocellular carcinoma (HCC) in chronic hepatitis C patients who achieved sustained virologic response (SVR) by therapy with interferon-free, direct-acting antivirals (DAAs). METHODS: This is a retrospective cohort study that included 567 patients who underwent antiviral therapy with an interferon-free DAA regimen and achieved SVR...
July 20, 2018: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/30006955/clinical-evaluation-of-a-novel-and-highly-sensitive-immunoassay-for-anti-hepatitis-b-core-antigen-using-a-fully-automated-immunochemical-analyzer
#20
Kyo Izumida, Atsushi Kaneko, Kazuya Takahashi, Shigeru Kusumoto, Tomoko Narita, Akiyoshi Takami, Shinsuke Iida, Katsumi Aoyagi, Yasuhito Tanaka
AIM: Recently, the measurement of hepatitis B surface antigen and anti-hepatitis B core antigen (HBcAb) and/or anti-hepatitis B surface antigen has been recommended before various therapies to identify patients at risk of hepatitis B virus (HBV) reactivation. However, a recent study reported that HBV reactivation occurred in HBcAb-negative patients, indicating that it is challenging to identify patients with a history of HBV infection using conventional HBcAb reagent. We developed a highly sensitive HBcAb (HBcAb-HS) assay for reducing the risk of HBV reactivation...
July 13, 2018: Hepatology Research: the Official Journal of the Japan Society of Hepatology
journal
journal
32820
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"